

## USE OF BARICITINIB FOR COVID-19 IN HOSPITALISED ADULTS DRUG GUIDELINE

Baricitinib (Olumiant®) is registered for use in Australia for the treatment of moderate-severe rheumatoid arthritis and moderate-severe atopic dermatitis but not for the treatment of COVID-19.<sup>1</sup> The [National COVID-19 Clinical Evidence Taskforce \(NCCET\)](#) (current as at 3/11/21) gives a conditional recommendation for use of baricitinib as an immunomodulator for adults hospitalised with COVID-19 who require supplemental oxygen.<sup>2</sup> (Certainty of evidence for outcomes: moderate for all-cause mortality; and, low for invasive ventilation or ECMO). The conditional recommendation is largely based on the results of the ACTT-2 trial<sup>7</sup> and the COV-BARRIER trial<sup>8</sup>, which indicated that baricitinib probably reduces the risk of death in patients not receiving mechanical ventilation or ECMO. Since then, the COV-BARRIER extension study<sup>9</sup> suggests baricitinib is safe and effective in patients hospitalised with COVID-19 requiring mechanical ventilation or ECMO. Use in pregnant or breastfeeding women or children and adolescents is NOT recommended outside randomised trials.<sup>2</sup>

This guideline requires endorsement by your local Drug and Therapeutics Committee (DTC) prior to implementation.

Supply of baricitinib for registered indications and clinical trials takes precedence over supply for off-label use outside of clinical trials.

This guideline aims to provide supportive information for clinicians if they decide to prescribe baricitinib for off-label use in hospitalised patients with COVID-19 when patients are not eligible for a clinical trial or when a clinical trial is not available.<sup>14</sup>

This guideline should be used in conjunction with the Baricitinib resources available [here](#):

- Individual Patient Use (IPU) Application Form,
- Outcomes Reporting Form,
- Patient Consent Form and
- Patient Information Leaflet.

For further information regarding consent see the NSW Health [Consent to Medical and Healthcare Treatment Manual](#), particularly Section 4.

Off-label use of baricitinib is not recommended in the Hospital in the Home setting or in community-based patients with COVID-19.

**Drug Class:** Janus Kinase (JAK) 1 and 2 inhibitor, disease modifying anti-rheumatic drug (DMARD), immunomodulator.<sup>1</sup>

### Authorised Prescribers:

- Immunologists,
- Infectious disease physicians,
- Respiratory physicians,
- Intensivists,

Other physicians in accordance with local governance regulations e.g. emergency physicians.

## Indication for applying this guidance<sup>2</sup>:

In accordance with relevant DTC approval, off-label baricitinib may be considered for patients with a current diagnosis of COVID-19:

- who require supplemental oxygen including those who may be intolerant of steroid therapy.

## Contraindications and Precautions<sup>1-6</sup>:

- **Hypersensitivity:** Contraindicated in patients with known hypersensitivity to baricitinib or any of the excipients in the product.
- **Thrombosis:** Baricitinib may increase the risk of venous thromboembolism (VTE). Thrombosis including pulmonary embolism, deep vein thrombosis and arterial thrombosis have been observed. Use with caution in individuals with an increased risk of thrombosis.
- **Haematological toxicity:**
  - Baricitinib may cause leucopenia, lymphopenia, neutropenia and anaemia. Cytopenias are generally reversible with treatment interruption. Do not commence if haemoglobin <80 g/L, lymphocyte<sup>6</sup> count <0.2 x 10<sup>9</sup>/L or neutrophil<sup>6</sup> count <0.5 x 10<sup>9</sup>/L. (Baricitinib use may still be considered if the patient is haemolysing).
- **Infection:**
  - Baricitinib is contraindicated in patients with serious active infections (other than COVID-19).
  - Baricitinib is associated with an increased risk of serious infections including bacterial, viral, fungal and opportunistic infections. There is an increased risk of infection when baricitinib is used with other immunosuppressive agents (see section on drug interactions).
  - Patients should be monitored for signs and symptoms of infection during and after treatment with baricitinib.
  - Tuberculosis has been reported in patients receiving baricitinib. Patients should be evaluated for latent tuberculosis.

N.B. Baseline testing for viral hepatitis, tuberculosis, strongyloides and HIV should be undertaken. Baricitinib treatment should NOT be delayed pending results of baseline tests.

- **Renal:** Baricitinib is not recommended for patients on dialysis or patients with acute kidney injury or eGFR<30mL/minute/1.73m<sup>2</sup>.<sup>1,8</sup> However baricitinib has been used in patients with eGFR 15-30mL/minute/1.73m<sup>2</sup>.<sup>8,10</sup> See **dose** section for further information.
- **Hepatic:** Baricitinib has not been studied in patients with severe hepatic impairment. It should only be used in patients with severe hepatic impairment if the potential benefit outweighs the potential risk of harm. See also monitoring section below.
- **Gastrointestinal (GI):**
  - GI perforations have been reported. Use with caution in patients at risk of GI perforation. Evaluate new onset abdominal symptoms.
- **Pregnancy and breastfeeding:** Avoid use. Baricitinib is a pregnancy [Category D](#) medication. A pregnancy test must be conducted in any COVID-19 positive woman of childbearing age in whom this therapy is being considered. (For treatment of pregnant and breastfeeding women with COVID-19, see National COVID-19 Clinical Evidence [Taskforce guidelines.](#))
- **Immunisations:**
  - Live vaccines should not be given concomitantly.

## Drug Interactions<sup>1,10-13</sup>:

Potential drug interactions have not been investigated in patients with COVID-19. Considerations:

- Baricitinib exposure is increased when baricitinib is used with strong OAT3 inhibitors e.g. probenecid and gemfibrozil.
- Additive immunosuppressive risk when used with other immunomodulatory agents e.g. methotrexate, corticosteroids\*, tocilizumab, adalimumab, rituximab and anakinra. Use of monoclonal antibodies targeting cytokines (e.g. TNF-alpha, interleukin-1, interleukin-6) or T-cells within the last 4 weeks and monoclonal antibodies targeting B-cells within the last 3 months are contraindicated. Given the potential for significant harm and no evidence of benefit for concurrent or sequential use of immunomodulatory therapy (with the exception of concurrent dexamethasone use), further/sequential immunomodulatory therapy is not recommended in a patient who continues to deteriorate while on baricitinib therapy, outside a clinical trial.  
\*Note: 6 mg dexamethasone (or equivalent corticosteroid) is standard of care treatment in COVID-19 patients in whom baricitinib is conditionally recommended.
- Clozapine: increased risk of agranulocytosis.
- Live vaccines should be avoided just prior to and during treatment with baricitinib. Specialist input should be obtained regarding timing of future vaccinations. Information is likely to evolve, see [Australian Immunisation Handbook](#) for further information or contact the [NSW Immunisation Specialist Service](#) (NSWISS) Advice Line (1800 679 477).

A variety of resources are available to check specific drug combinations, e.g. Liverpool COVID-19 Drug Interactions [tool](#) and Micromedex drug interaction tool ([CIAP link](#)). Contact the local pharmacy department or medicines information service for tailored advice.

## Storage and Presentation<sup>1</sup>:

Store below 30°C in original package. Available as:

- 2 mg film-coated tablets
- 4 mg film-coated tablets.

## Dose<sup>1,8,10</sup>:

The recommended dose is:

4 mg orally ONCE DAILY for up to 14 days or until hospital discharge, whichever comes first.

Dose adjustments

- Renal impairment:
  - Halve dose to 2 mg orally ONCE DAILY when eGFR = 30 - 60 mL/min/1.73m<sup>2</sup>.
  - Reduce dose to 1 mg orally ONCE DAILY when eGFR = 15 - 30 mL/min/1.73m<sup>2</sup>.<sup>10</sup>
- Patients taking strong OAT3 inhibitors, such as probenecid or gemfibrozil:
  - Halve the dose

## Preparation and Administration<sup>1,10,15,16</sup>:

- Can be given without regard to food.
- Do not crush or break the tablet\*\* (see **handling** section below).
- For patients who are unable to swallow whole tablets, place tablet(s) to achieve desired dose in a suitable container with room temperature water (see Table 1) and disperse by gentle swirling until an even suspension is formed. Tablet may take 5 minutes to completely disperse.<sup>16</sup>
- Dispersed tablets are stable in water for up to 4 hours; however, the solution should be administered immediately whenever possible. The container should be rinsed with additional room temperature water (see Table 1) and these contents also administered.

**Table 1: Dispersion instructions for 2 mg and 4 mg baricitinib tablet(s)<sup>16</sup>**

Administration via	Dispersion volume of water	Container rinse volume
Oral dispersion	5 - 10 mL	At least 5 mL
Gastrostomy tube	15 mL	At least 15 mL
Nasogastric tube <sup>~</sup>	30 mL	At least 15 mL

<sup>~</sup> To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken several times during administration.

### Please note

For a 1 mg dose it is recommended to:

- Give double the dose every second day e.g. a 1 mg once daily dose is given as 2 mg every second day. This alternate day dosing option is based on the [RECOVERY trial protocol](#)<sup>17</sup> and Eli Lilly Australia communication<sup>18</sup>. Cutting Olumiant tablets is not recommended because a) tablet is not scored; b) may present an occupational hazard; c) could lead to inaccurate dosing; and, d) unknown stability issues of remaining half tablet. Moreover, baricitinib is very slightly to slightly soluble. It is not recommended to take a part-dose from a dispersed tablet.<sup>16</sup>

### Handling<sup>10,15,16,19,20</sup>

- **Intact** baricitinib tablets can be handled with standard precautions for handling of oral medications.
- Occupational exposure to **non-intact** tablets (i.e. dispersed, **\*\*crushed** or **\*\*broken**) may be harmful by posing a reproductive hazard. Staff who are actively trying to conceive or who are pregnant or breast-feeding should not prepare or handle a dispersed dose.
- For all other staff, use standard Personal Protective Equipment (PPE) (or refer to local guidelines) if preparation or administration of a dispersed tablet is required.

### Monitoring Requirements<sup>3,10</sup>:

- Baseline FBC (with differential)
- LFTs
- EUCs
- Monitor for adverse effects (see below section) – including FBC and LFTs.

Interrupt treatment if:

- Neutrophil count  $<0.5 \times 10^9$  cells/L,
- Lymphocyte count  $<0.2 \times 10^9$  cells/L,
- Haemoglobin  $<80$  g/L.
- Increases in ALT or AST are observed and drug-induced liver injury is suspected

### Adverse Effects<sup>¥3</sup>:

It may be difficult to distinguish between adverse effects of baricitinib and signs and symptoms of COVID-19. As the proposed use is off-label, it is important to document and report all (from possible to confirmed) adverse effects experienced by the patient during treatment to inform its safety profile and future use.

- **Common (>1%):**  
Infections (including serious and opportunistic), hypercholesterolaemia, thrombocytosis (not associated with thrombotic events), nausea (especially in first 2 weeks), abdominal pain, headache, increased creatine kinase.
- **Infrequent (0.1–1%):**  
Thrombosis, neutropenia, lymphopenia, anaemia, acne, vomiting, hypertriglyceridaemia, increased liver enzymes.

¥ Refer to Product Information for complete list of possible adverse effects.

## Reporting:

Access via the IPU pathway will enable appropriate medicines governance and ensure the collection and analysis of patient outcomes and systematic monitoring of medicines use. The prescribing clinician is responsible for reporting medication errors and adverse events occurring as a result of baricitinib treatment:

- Adverse events related to medicines should be reported to the [TGA](#) and via the hospital ims+ or Riskman system.
- Approval of off-label baricitinib IPU requires reporting of clinical outcomes. Prescribing declarations or IPU applications and outcome reporting should occur as per local governance processes. A NSW TAG-developed drug registry using an online IPU application and outcome reporting processes has been developed. See <https://www.nswtag.org.au/covid-19-medicines-resources/>. Contact your local DTC or pharmacist for further information.

## Summary of amendments/updates made in version 1.3 9 November 2021:

- Introductory section (page 1) and indications section (page 2): updated [NCCET](#) guideline recommendation by removing “and/or non-invasive ventilation” to include use in patients hospitalised with COVID-19 who require mechanical ventilation or ECMO.
- Preparation & Administration section (page 4): removal of cutting tablet option and added citation for Eli Lilly communication.

## References:

1. Therapeutic Goods Administration. Australian Product Information - Olumiant (Baricitinib). <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01225-1&d=20210722172310101&d=20210728172310101>. Published 2021. Accessed July 22, 2021.
2. National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. <https://covid19evidence.net.au/#living-guidelines>. Published 2021. Accessed 2021.
3. Australian Medicines Handbook. Baricitinib. <https://amhonline.amh.net.au/acs.hcn.com.au/chapters/rheumatological-drugs/immunomodulating-drugs/immunosuppressants-rheumatology/baricitinib>. Published 2021. Accessed July 27, 2021.
4. National Institutes of Health. COVID-19 Treatment Guidelines: Kinase Inhibitors: Baricitinib and Other Janus Kinase Inhibitors, and Bruton's Tyrosine Kinase Inhibitors. <https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors>. Published 2021. Accessed July 27, 2021.
5. The U.S. Food and Drug Administration (FDA). Baricitinib Approved Drug Label. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/207924s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207924s002lbl.pdf). Published 2020. Accessed July 30, 2021.
6. The U.S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers, Emergency Use Authorization (EUA) of Baricitinib (last updated October 2021). <http://pi.lilly.com/eua/baricitinib-eua-factsheet-hcp.pdf>. Accessed 2021 October 10.
7. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *New England Journal of Medicine*. 2020;384(9):795-807.
8. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med*. 2021;9(10):e102. doi:10.1016/S2213-2600(21)00331-3. Published 2021 September 1.
9. Ely EW, Ramanan AV, Kartman CE, et al. Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial. *medRxiv*. 2021:2021.2010.2011.21263897.
10. The U.S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers, Emergency Use Authorization (EUA) of Baricitinib. <https://www.fda.gov/media/143823/download>. Published 2020. Accessed July 22, 2021.
11. University of Liverpool. COVID-19 Drug Interaction Checker. <https://www.covid19-druginteractions.org/>. Published 2020. Accessed July 22, 2021.
12. Micromedex. Drug Interaction Results For Baricitinib. IBM Micromedex [https://www.micromedexolutions.com/acs.hcn.com.au/micromedex2/librarian/CS/CCC6AA/ND\\_PR/evidencexpert/ND\\_P/evidencexpert/DUPLICATIONSHIELDSYNC/609F9E/ND\\_PG/evidencexpert/ND\\_B/evidencexpert/ND\\_AppProduct/evidencexpert/ND\\_T/evidencexpert/PFActionId/evidencexpert.FindDrugInteractions?navitem=topInteractions&isToolPage=true](https://www.micromedexolutions.com/acs.hcn.com.au/micromedex2/librarian/CS/CCC6AA/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/609F9E/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.FindDrugInteractions?navitem=topInteractions&isToolPage=true). Accessed July 27, 2021.
13. UK Renal Pharmacy Group. The Renal Drug Database: The ultimate prescribing guide for renal practitioners. BARICITINIB monograph. CRC Press. <https://renaldrugdatabase.com/acs.hcn.com.au/monographs/baricitinib>. Accessed Aug 3, 2021.
14. Council of Australian Therapeutic Advisory Groups (CATAG). Rethinking medicines decision-making in Australian Hospitals. Guiding principles for the quality use of off-label medicines. 2013. <http://www.catag.org.au/wp-content/uploads/2012/08/OKA9963-CATAG-Rethinking-Medicines-Decision-Making-final1.pdf>.
15. Eli Lilly Australia Pty Ltd. Baricitinib: Alternative Administration and Extemporaneous Preparation. In. Response to a request for information on Olumiant® and 1) splitting and crushing, 2) the tablet strength that can be dispersed in water, 3) the recommended nasogastric tube size and 4) the stability of dispersed tablets in water. ed.
16. The Australian Don't Rush to Crush Handbook (Fourth Edition): Baricitinib. 2021. [https://www.shpa.org.au/sites/default/files/uploaded-content/field\\_f\\_content\\_file/baricitinib\\_update\\_october\\_2021\\_final.pdf](https://www.shpa.org.au/sites/default/files/uploaded-content/field_f_content_file/baricitinib_update_october_2021_final.pdf). Accessed 2021 October 10.
17. The RECOVERY Collaborative Group. Randomised Evaluation of COVID-19 Therapy (RECOVERY) Protocol V16.1 2021-07-08. 2021. <https://www.recoverytrial.net/files/professional-downloads/recovery-protocol-v16-1-2021-07-08.pdf>.
18. Eli Lilly Australia Pty Ltd. Fact Sheet for Healthcare Providers. Unapproved Use of Baricitinib in Hospitalised Patients with COVID-19. Version 1.0 Approved 6th August 2021.
19. National Institute for Occupational Safety and Health (NIOSH). NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. <https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf?id=10.26616/NIOSH-PUB2016161>. Accessed Aug 2, 2021.
20. Peter MacCallum Cancer Centre Victoria Australia. Procedure: Safe Handling of Cytotoxic, Monoclonal Antibody & Hazardous Non-Cytotoxic Drugs. [https://www.petermac.org/sites/default/files/media-uploads/iPolicy%20Safe%20handling%20of%20hazardous%20drugs\\_UPDATE%20April%202020.docconverted.pdf](https://www.petermac.org/sites/default/files/media-uploads/iPolicy%20Safe%20handling%20of%20hazardous%20drugs_UPDATE%20April%202020.docconverted.pdf). Published 2020. Accessed Aug 2, 2021.